The Phase II trial of the vaccine ARCoV, jointly developed by Suzhou Abogen Biosciences (AbogenBio), the Institute of Military Medicine under the Academy of Military Sciences and Walvax Biotechnology Co., is reported to run smoothly and drawing to a close. The late-stage trial will begin next month overseas with close cooperation with Chinese clinical contract research organization Tigermed, Starting from the third quarter of the year, the annual production capacity of ARCoV is said to reach 120 million doses.

Xinhua news release, April 16, 2021